<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highlights of This Issue</td>
<td>753</td>
<td></td>
</tr>
<tr>
<td>SPECIAL FEATURES</td>
<td>CCR Translations</td>
<td></td>
</tr>
</tbody>
</table>
| 755 | Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal  
Rekha Gyanchandani and Seungwon Kim  
See article, p. 929                                                                                                                                                                                                 |       |
| Molecular Pathways | Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed By Oncolytic Vesiculoviruses  
Douglas J. Mahoney and David F. Stojdl                                                                                                                                                             |       |
| Review | The Definition of Primary and Secondary Glioblastoma  
Hiroko Ohgaki and Paul Kleihues                                                                                                                                                                          |       |
| HUMAN CANCER BIOLOGY | Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas  
Mark L. McCleland, Adam S. Adler, Laura Deming, Ely Cosino, Leslie Lee, Elizabeth M. Blackwood, Margaret Solon, Janet Tao, Li Li, David Shames, Erica Jackson, William F. Forrest, and Ron Firestein                                                                 | 773   |
| 785 | Reciprocal Interactions between Tumor-Associated Macrophages and Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer  
Guanhua Rao, Hongyi Wang, Baowei Li, Li Huang, Danfeng Xue, Xiaohui Wang, Haijing Jin, Jun Wang, Yushan Zhu, Youyong Lu, Lei Du, and Quan Chen                                                                                                                                 |       |
| 798 | SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells  
Michael S. Leibowitz, Raghavendra M. Srivastava, Pedro A. Andrade Filho, Ann Marie Egloff, Lin Wang, Raja R. Seethala, Soldano Ferrone, and Robert L. Ferris                                                                                                                                 |       |
| CANCER THERAPY: PRECLINICAL | Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer  
| 821 | Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice  
Evita van de Steeg, Anita van Esch, Els Wagenaar, Kathryn E. Kenworthy, and Alfred H. Schinkel                                                                                                                                                          |       |
| 833 | Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363  
Francois Lamoureux, Christian Thomas, Claire Crafter, Masafumi Kumano, Fan Zhang, Barry R. Davies, Martin E. Gleave, and Amina Zoubeidi                                                                                                                                 |       |
| 845 | Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells  
Hiroyoshi Tamaguchi, Jennifer L. Hsu, Chun-Te Chen, Ying-Nai Wang, Ming-Chuan Hsu, Shih-Shin Chang, Yi Du, How-Wen Ko, Roy Herbst, and Mien-Chie Hung                                                                                                                                 |       |
| 855 | Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts  
Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
Nilesh A. Patankar, Julia Pritchard, Mariska van Grinsven, Maryam Osooly, and Marcel B. Bally

IMAGING, DIAGNOSIS, PROGNOSIS

DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett’s Esophagus
Muhammad A. Alvi, Xinxue Liu, Maria O’Donovan, Richard Newton, Lorenz Wernisch, Nicholas R. Shannon, Kareem Shariff, Massimiliano di Pietro, Jacques J.G.H.M. Bergman, Krish Ragunath, and Rebecca C. Fitzgerald

The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Malgorzata Czystowska, William Gooding, Miroslaw J. Szczepanski, Andres Lopez-Abaitero, Robert L. Ferris, Jonas T. Johnson, and Theresa L. Whiteside

CANCER THERAPY: CLINICAL

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon, Morris D. Groves, Patrick Y. Wen, Louis Nabors, Tom Mikkelson, Steve Rosenfeld, Jeffrey Raizer, Jorge Barriuso, Roger E. McLendon, Bo Ma, C. Martin Curtis, Mohammed M. Dar, and Johann de Bono

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde, Adrian M. Jubbi, Dafeng Chen, Nicole F. Li, Ya Gowra Meng, Coen Bernards, Rebecca Elliott, Stefan J. Scherer, and Daniel S. Chen

See commentary, p. 755

LETTERS TO THE EDITOR

Long-term Prospective Population PK Study in GIST Patients—Letter
Etienne Chatelut, Peggy Gandia, Verena Gotta, and Nicolas Widmer

Long-term Prospective Population PK Study in GIST Patients—Response
Ron H.J. Mathijssen, Peter de Bruijn, Karel Eechoute, and Alex Sparreboom

CORRECTION

Correction: Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Andrew X. Zhu, Philip J. Gold, Anthony B. El-Khouri, Thomas A. Abrams, Hideo Morikawa, Norihisa Ohishi, Toshihiko Ohtomo, and Philip A. Philip

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Reda Z. Mahfouz, Ania Jankowska, Qutba Ebrahem, Xiaorong Gu, Valeria Visconte, Ali Tabarroki, Pramod Terse, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engkelke, Mikhail A. Sekeres, Ramon Tiu, Jaroslav Maciejewski, Tomas Radirovoyvitch, and Yogen Saunthararajah
ABOUT THE COVER

The image displays a human prostate cell line (PC-3) that has been stained with antibodies against the autophagy marker Light Chain 3 (LC3; green) after rapamycin treatment. During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles, as shown by green puncta. Tumor cell nuclei are visualized by DAPI (blue). For details, see the article by Lamoureux and colleagues on page 833 of this issue.